<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Biotherapy</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Biotherapy</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский биотерапевтический журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-9784</issn><issn publication-format="electronic">1726-9792</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1085</article-id><article-id pub-id-type="doi">10.17650/1726-9784-2018-17-2-31-40</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL REPORTS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Subcutaneous and orthotopic xenograft models of human bladder carcinoma in nude mice for epidermal growth factor receptor-targeted treatment</article-title><trans-title-group xml:lang="ru"><trans-title>Модели подкожного и ортотопического ксенографтов рака мочевого пузыря человека у мышей nude для исследования воздействий, нацеленных на рецептор эпидермального фактора роста</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Vorontsova</surname><given-names>M. S.</given-names></name><name xml:lang="ru"><surname>Воронцова</surname><given-names>М. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>3 2nd Botkinskiy Proezd, Moscow 125284</italic></p></bio><bio xml:lang="ru"><p><italic>125284 Москва, 2-й Боткинский проезд, 3</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Karmakova</surname><given-names>T. A.</given-names></name><name xml:lang="ru"><surname>Кармакова</surname><given-names>Т. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>3 2nd Botkinskiy Proezd, Moscow 125284</italic></p></bio><bio xml:lang="ru"><p><bold>Татьяна Анатольевна Кармакова </bold></p><p><italic>125284 Москва, 2-й Боткинский проезд, 3</italic></p></bio><email>kalmar123@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Plotnikova</surname><given-names>E. A.</given-names></name><name xml:lang="ru"><surname>Плотникова</surname><given-names>Е. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>3 2nd Botkinskiy Proezd, Moscow 125284</italic></p></bio><bio xml:lang="ru"><p><italic>125284 Москва, 2-й Боткинский проезд, 3</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Morozova</surname><given-names>N. B.</given-names></name><name xml:lang="ru"><surname>Морозова</surname><given-names>Н. Б.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>3 2nd Botkinskiy Proezd, Moscow 125284</italic></p></bio><bio xml:lang="ru"><p><italic>125284 Москва, 2-й Боткинский проезд, 3</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Abakumov</surname><given-names>M. A.</given-names></name><name xml:lang="ru"><surname>Абакумов</surname><given-names>М. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>1 Ostrovitianov</italic><italic>а</italic><italic>st., Moscow 117997, </italic></p><p><italic>4 Leniskiy Prospekt, Moscow 119094</italic></p></bio><bio xml:lang="ru"><p><italic>117997 Москва, ул. Островитянова, 1, </italic></p><p><italic>119049 Москва, Ленинский пр-т, 4 </italic></p></bio><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Yakubovskaya</surname><given-names>R. I.</given-names></name><name xml:lang="ru"><surname>Якубовская</surname><given-names>Р. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>3 2nd Botkinskiy Proezd, Moscow 125284</italic></p></bio><bio xml:lang="ru"><p><italic>125284 Москва, 2-й Боткинский проезд, 3</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Alexeev</surname><given-names>B. Ya.</given-names></name><name xml:lang="ru"><surname>Алексеев</surname><given-names>Б. Я.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>3 2nd Botkinskiy Proezd, Moscow 125284</italic></p></bio><bio xml:lang="ru"><p><italic>125284 Москва, 2-й Боткинский проезд, 3</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">P. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Center of Radiology, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «РНИМУ им. Н.И. Пирогова» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">National University of Science and Technology “MISiS”</institution></aff><aff><institution xml:lang="ru">НИТУ «МИСиС»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2018-11-24" publication-format="electronic"><day>24</day><month>11</month><year>2018</year></pub-date><volume>17</volume><issue>2</issue><issue-title xml:lang="ru"/><fpage>31</fpage><lpage>40</lpage><history><date date-type="received" iso-8601-date="2018-11-23"><day>23</day><month>11</month><year>2018</year></date><date date-type="accepted" iso-8601-date="2018-11-23"><day>23</day><month>11</month><year>2018</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://bioterapevt.abvpress.ru/jour/article/view/1085">https://bioterapevt.abvpress.ru/jour/article/view/1085</self-uri><abstract xml:lang="en"><p><bold>Introduction. </bold>Approaches based on the principles of a targeted therapy are considered a promising strategy that is capable to improve the effectiveness of treatment for bladder cancer (BC) patients.</p><p><bold>The purpose </bold>of the study was to establish an orthotopic xenograft model of human BC in mice and to prove its suitability for experimental examination of drugs targeting the epidermal growth factor receptor (EGFR).</p><p><bold>Materials and methods. </bold>The objects of the study were ectopic subcutaneous and orthotopic human BC xenografts established using EJ and 5637 human BC cell lines. The growth of orthotopic xenografts in vivo was assessed by magnetic resonance imaging. Tumor tissues were investigated using histological and immunohistochemical techniques.</p><p><bold>Results. </bold>It was shown that EJ and 5637 xenografts exhibit a good reproducibility, a sufficient blood supply of the tumor tissues, a high level of EGFR expression, and different pattern of a subcellular receptor localization. Implantation and subsequent proliferation of human EJ or 5637 cells in the murine bladder mucosa presumably results in muscle-non-invasive tumor formation.</p><p><bold>Conclusions. </bold>The EJ and 5637 xenograft models can be useful for investigation of the efficacy of EGFR-targeted biotherapeutic treatments.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение. </bold>Подходы, основанные на принципах таргетной терапии, рассматриваются как перспективное направление создания новых методов лечения, способных увеличить эффективность лечения больных раком мочевого пузыря (РМП).</p><p><bold>Цель исследования </bold>– получение ортотопической модели РМП человека у мышей линии nude и обоснование ее пригодности для экспериментального изучения таргетных препаратов, нацеленных на рецептор эпидермального фактора роста (РЭФР).</p><p><bold>Материалы и методы. </bold>Объектом исследования служили эктопические подкожные и ортотопические ксенографты РМП человека, полученные с использованием культивируемых клеток линий EJ и 5637. Рост ортотопических ксенографтов in vivo оценивали методом магнитно-резонансной томографии. Для исследования тканей опухолей использованы методы гистологического и иммуногистохимического анализа.</p><p><bold>Результаты. </bold>Показано, что как эктопические, так и ортотопические ксенографты EJ и 5637 характеризуются высокой воспроизводимостью модели, хорошим кровоснабжением ткани, высоким уровнем экспрессии РЭФР и отличаются локализацией рецептора в опухолевых клетках. Пролиферация клеток EJ и 5637 в слизистой оболочке мочевого пузыря мышей при их внутрипузырной имплантации преимущественно приводит к образованию мышечно-неивазивной формы опухоли.</p><p><bold>Заключение. </bold>Ксенографты EJ и 5637 у иммунодефицитных мышей могут быть использованы в качестве моделей РМП человека для изучения эффективности биотерапевтических воздействий, использующих в качестве мишени РЭФР.</p></trans-abstract><kwd-group xml:lang="en"><kwd>bladder cancer</kwd><kwd>orthotopic xenograft tumor model</kwd><kwd>nude mice</kwd><kwd>epidermal growth factor receptor</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>рак мочевого пузыря</kwd><kwd>ксенографт опухоли</kwd><kwd>мыши nude</kwd><kwd>рецептор эпидермального фактора роста</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Malignant tumors in Russia in 2015 (morbidity and mortality). Ed. A.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: Hertsen MORI, branch of NMRRC MH RF. 2017. 250 p. (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Злокачественные новообразования в России в 2015 г. (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России, 2017. 250 с.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><mixed-citation>Torre L.A., Siegel R.L., Ward E.M., Jemal A. Global cancer incidence and mortality rates and trends – an update. Cancer Epidemiol Biomarkers Prev 2016;25:16–27. DOI: 10.1158/1055-9965.EPI-15-0578. PMID: 26667886.</mixed-citation></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Alekseev B.Ya., Andreeva Yu.Yu., Novikova I.V. Factors predicting survival in patients with nonmuscle invasive bladder cancer. Onkourologiya = Oncourology 2013;9(1):34–42 (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Алексеев Б.Я., Андреева Ю.Ю., Новикова И.В. Факторы прогноза выживаемости у больных немышечно-инвазивным раком мочевого пузыря. Онкоурология 2013;9(1):34–42. DOI: http://dx.doi.org/10.17650/1726-9776-2013-9-1-34-42.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><mixed-citation>Chou R., Selph S., Buckley D.I. et al. Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: A systematic review and meta-analysis. J Urol 2017;197(5):1189–99. DOI: 10.1016/j.juro.2016.12.090. PMID: 28027868.</mixed-citation></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Komyakov B.K., Guliev B.G., Sergeev A.V. Survival of patients with bladder cancer after radical cystectomy. Onkourologiya = Oncourology 2016;12(1):29–35 (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Комяков Б.К., Гулиев Б.Г., Сергеев А.В. и др. Выживаемость больных раком мочевого пузыря после радикальной цистэктомии. Онкоурология 2016;12(1):29–35. DOI: http://dx.doi.org/10.17650/1726 -9776-2016-12-1-29-35</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><mixed-citation>Lobo N., Mount C., Omar K. et al. Landmarks in the treatment of muscleinvasive bladder cancer. Nat Rev Urol 2017;14(9):565–74. DOI: 10.1038/nrurol.2017.82. PMID: 28675174.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Sanli O., Dobruch J., Knowles M.A. et al. Bladder cancer. Nat Rev Dis Primers 2017;3:17022. DOI: 10.1038/nrdp.2017.22. PMID: 28406148.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Ghosh M., Brancato S.J., Agarwal P.K., Apolo A.B. Targeted therapies in urothelial carcinoma. Curr Opin Oncol 2014;26(3):305–20. DOI: 10.1097/CCO.0000000000000064. PMID: 24685646.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Weintraub M.D., Vourganti S., Li Q. et al. Targeting the epidermal growth factor receptor in bladder cancer. J Carcinogene Mutagene 2013;4:143. DOI: 10.4172/2157–2518.1000143.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Mooso B.A., Vinall R.L., Mudryj M. et al. The role of EGFR family inhibitors in muscle invasive bladder cancer: a review of clinical data and molecular evidence. J Urol 2015;193(1):19–29. DOI: 10.1016/j.juro.2014.07.121. PMID: 25158272.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Chaux A., Cohen J.S., Schultz L. et al. High epidermal growth factor receptor immunohistochemical expression in urothelial carcinoma of the bladder is not associated with EGFR mutations in exons 19 and 21: a study using formalin-fixed, paraffin-embedded archival tissues. Hum. Pathol 2012;43(10):1590–5. DOI: 10.1016/j.humpath.2011.11.016. PMID: 22406363.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Carlsson J., Wester K., De La Torre M. et al. EGFR-expression in primary urinary bladder cancer and corresponding metastases and the relation to HER2-expression. On the possibility to target these receptors with radionuclides. Radiol Oncol 2015;49(1):50–8. DOI: 0.2478/raon-2014–0015. PMID: 25810701.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Hussain M., Daignault S., Agarwal N. et al. A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. Cancer 2014;120(17):2684–93. DOI: 10.1002/cncr.28767. PMID: 24802654.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Miller K., Morant R., Stenzl A. et al. A phase II study of the Central European Society of Anticancer-Drug Research (CESAR) Group: Results of an openlabel study of gemcitabine plus cisplatin with or without concomitant or sequential gefitinib in patients with advanced or metastatic transitional cell carcinoma of the urothelium. Urol Int 2016;96(1):5–13. DOI: 10.1159/000381589. PMID: 26068576.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Powles T., Huddart R.A., Elliott T. et al. Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1/2-positive metastatic bladder cancer. J Clin Oncol 2017;35(1):48–55. DOI: 10.1200/JCO.2015.66.3468. PMID: 28034079.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Pfost B., Seidl C., Autenrieth M. et al. Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice. J Nucl Med 2009;50(10): 1700–8. DOI: 10.2967/jnumed.109.065961. PMID: 19793735.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Yang X., Kessler E., Su L.J. et al. Diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancer. Clin Cancer Res 2013;19(1):148–57. DOI: 10.1158/1078-0432.CCR-12-1258. PMID: 23172881.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Grivas P.D., Day K.C., Karatsinides A. et al. Evaluation of the antitumor activity of dacomitinib in models of human bladder cancer. Mol Med 2013;19:367–76. DOI: 10.2119/molmed.2013.00108. PMID: 24166682.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Tsai Y.C., Ho P.Y., Tzen K.Y. et al. Synergistic blockade of EGFR and HER2 by new-generation EGFR tyrosine kinase inhibitor enhances radiation effect in bladder cancer cells. Mol Cancer Ther 2015;14(3):810–20. DOI: 10.1158/1535-7163.MCT-130951. PMID: 25589492.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Railkar R., Krane L.S., Li Q.Q. et al. Epidermal growth factor receptor (EGFR) targeted photoimmunotherapy (PIT) for the treatment of EGFR expressing bladder cancer. Mol Cancer Ther 2017;16(10):2201–14. DOI: 10.1158/1535-7163.MCT-160924. PMID: 28619755.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Arantes-Rodrigues R., Colaço A., Pinto-Leite R. et al. In vitro and in vivo experimental models as tools to investigate the efficacy of antineoplastic drugs on urinary bladder cancer. Anticancer Res 2013;33(4):1273–96. PMID: 23564765.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Dominguez-Escrig J.L., Kelly J.D., Neal D.E. et al. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer. Clin Cancer Res 2004;10(14):4874–84. DOI: 10.1158/1078-0432.CCR-04-0034. PMID: 15269164.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Mansure J.J., Nassim R., Chevalier S. et al. A novel mechanism of PPAR gamma induction via EGFR signalling constitutes rational for combination therapy in bladder cancer. PLoS One 2013;8(2):e55997. DOI: 10.1371/journal.pone.0055997. PMID: 23409107.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Bhuvaneswari R., Gan Y.Y., Soo K.C., Olivo M. Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response. Mol Cancer 2009;8:94. DOI: 10.1186/1476-4598-8-94. PMID: 19878607.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Wu M.L., Li H., Yu L.J. et al. Short-term resveratrol exposure causes in vitro and in vivo growth inhibition and apoptosis of bladder cancer cells. PLoS One 2014;9(2):e89806. DOI: 10.1371/journal.pone.0089806. PMID: 24587049.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Fazel J., Rötzer S., Seidl C. et al. Fractionated intravesical radio immunotherapy with (213) Bi-anti-EGFR-MAb is effective without toxic side-effects in a nude mouse model of advanced human bladder carcinoma. Cancer Biol Ther 2015;16(10):1526–34. DOI: 10.1080/15384047.2015.1071735. PMID: 26177233.</mixed-citation></ref><ref id="B27"><label>27.</label><citation-alternatives><mixed-citation xml:lang="en">Guidelines for laboratory animals and alternative models in biomedical research. Ed. N.N. Karkishchenko, S.V. Grachev. Moscow: Profil-2S Ltd, 2010. 358 p. (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Руководство по лабораторным животным и альтернативным моделям в биомедицинских исследованиях. Под ред. Н.Н. Каркищенко, С.В. Грачева. М.: Профиль-2С, 2010. 358 с.</mixed-citation></citation-alternatives></ref><ref id="B28"><label>28.</label><mixed-citation>Chan E., Patel A., Heston W., Larchian W. Mouse orthotopic models for bladder cancer research. BJU Int 2009;104(9):1286–91. DOI: 10.1111/j.1464-410X.2009.08577.x. PMID: 19388981.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Einama T., Ueda S., Tsuda H. et al. Membranous and cytoplasmic expression of epidermal growth factor receptor in metastatic pancreatic ductal adenocarcinoma. Exp Ther Med 2012;3:931–36. DOI: 10.3892/etm.2012.518. PMID: 22969995.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Ueda S., Ogata S., Tsuda H. et al. The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 2004;29:e1–8. PMID: 15211117.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Kankaya D., Kiremitci S., Tulunay O., Baltaci S. Prognostic impact of epidermal growth factor receptor on clear cell renal cell carcinoma: Does it change with different expression patterns? Indian Journal of Pathology and Microbiology 2016;59:35–40. DOI: 10.4103/0377-4929.178219. PMID: 26960632.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Kallio J.P., Hirvikoski P., Helin H. et al. Membranous location of EGFR immunostaining is associated with good prognosis in renal cell carcinoma. Br J Cancer 2003;89:1266–9. DOI: 10.1038/sj.bjc.6601241. PMID: 14520458.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Tomas A., Futter C.E., Eden E.R. EGF receptor trafficking: consequences for signaling and cancer. Trends Cell Biol 2014;24(1):26–34. DOI: 10.1016/j.tcb.2013.11.002. PMID: 24295852.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Pirker R., Pereira J.R., von Pawel J. et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. The Lancet Oncology. 2012;13:33–42. DOI: 10.1016/S1470-2045(11)70318-7. PMID: 22056021</mixed-citation></ref></ref-list></back></article>
